<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="remains active. Highlights â€¢Five viral infectious diseases with high global" exact="prevalence" post="are discussed. â€¢Those diseases include influenza, CHB, AIDS, SARS,"/>
 <result pre="â€¢Potential of peptides in therapy, vaccine, and diagnostic of viral" exact="infection" post="diseases are addressed. â€¢Peptide-based candidates in pre-clinical and clinical"/>
 <result pre="repeat CHR, C-terminal heptad repeat WHO, World Health Organization PCR," exact="polymerase chain reaction" post="qRT-PCR, quantitative real-time PCR Keywords Peptides Influenza Chronic hepatitis"/>
 <result pre="organizations have put together countless initiatives, including treatment, prevention, and" exact="detection" post="strategies to combat the spread and re-emergence of viral"/>
 <result pre="enhance the immune response [140,107,135]. Moreover, peptides are employed in" exact="detection" post="assays to diagnose various infectious diseases. Peptide-based diagnostic reagents"/>
 <result pre="Hemagglutinin (HA) and Neuraminidase (NA) play key roles during viral" exact="infection" post="[82,187]. Based on the different combinations of HA and"/>
 <result pre="HA1 and HA2 subunits linked by a disulfide bond. The" exact="infection" post="event is triggered by HA1 binding to sialylated receptors"/>
 <result pre="[67] and it is currently in clinical trials for the" exact="treatment" post="of COVID-19. It is important to note that the"/>
 <result pre="specificity and efficacy. The developments of antiviral peptides for the" exact="treatment" post="of influenza is discussed next. Naturally occurring AMPs, such"/>
 <result pre="milk was shown to bind to HA and inhibit the" exact="infection" post="of influenza subtypes H1N1 and H3N2. By molecular docking,"/>
 <result pre="17 was more active than the parental peptide in the" exact="neutralization assay" post="in MDCK cells [184]. The second example, a 20-residue"/>
 <result pre="peptide bound to NA with nanomolar affinity and inhibited H1N1" exact="infection" post="at Î¼M concentration in MDCK cells. Administration of the"/>
 <result pre="Pre-clinical [231] EB RRKKAAVALLPAVLLALLAP fibroblast growth factor 4 3âˆ’10 Î¼M" exact="hemagglutination" post="inhibition assay Pre-clinical [106] FP-4 RRKKWLVFFVIFYFFR Tyrosine kinase inhibitor"/>
 <result pre="B and T cell-specific immune responses and offers protection against" exact="infection" post="with different influenza strains, including H5N1 strain. M-001 is"/>
 <result pre="both of which can protect from severe disease symptoms upon" exact="infection" post="[90]. The currently used influenza diagnostic tests are based"/>
 <result pre="influenza diagnostic tests are based on molecular assays and antigen" exact="detection" post="[202]. FDA-licensed tests are designed to detect and differentiate"/>
 <result pre="developed approach is a peptide-based molecular beacon (PEP-MB) for the" exact="detection" post="of Influenza type A using fluorescence resonance energy transfer"/>
 <result pre="is emitted and detected by the beacon [122]. In another" exact="detection" post="method, sialic acid-mimic pentapeptide (ARLPR) identified by phage display"/>
 <result pre="is immobilized on boron-doped diamond electrodes using click chemistry. Electrochemical" exact="detection" post="of HA binding to the peptide indicates the presence"/>
 <result pre="a critical role in HBV replication [165,146,75]. The current FDA-approved" exact="treatment" post="for CHB is based on two main strategies: 1)"/>
 <result pre="with a 90 % relapse rate within a year after" exact="treatment" post="is stopped. IFN-Î± was expected to provide a gold"/>
 <result pre="has recommends the orally administrated tenofovir or entecavir for the" exact="treatment" post="of CHB due to their minimal drug resistance and"/>
 <result pre="Mdm2 is disassociated and p53 levels are increased [113,120,170]. PTD-p37" exact="treatment" post="reduced HBsAg levels and viral proliferation in vitro and"/>
 <result pre="[170,61,125]. Peptides have also demonstrated significant potential in interrupting virus" exact="infection" post="in preclinical research. HBsAg is composed of three types"/>
 <result pre="protein with S domain only. The pre-S1 domain initiates virus" exact="infection" post="by binding to the host receptor called sodium taurocholate"/>
 <result pre="6â€&quot;17 residues were identified from a random peptide integrated discovery" exact="screening" post="platform. Among the top ten candidates that were selected"/>
 <result pre="from pre-S1, Myrcludex-B, that binds to NTCP and inhibit HBV" exact="infection" post="in cell culture and animal models [203,76,159]. Liposomal formulation"/>
 <result pre="The five most potent drugs were tested in the HBV" exact="infection" post="assay using human hepatic cell line HepaRG. They are"/>
 <result pre="Blue 6B. All five drugs were shown to block HBV" exact="infection" post="at similar levels of potency. Although, Donker's unique approach"/>
 <result pre="peptide inhibitors of virus pre-S1 were also investigated for the" exact="treatment" post="of CHB. A short peptide B10 (SGSGLRNIRST) was identified"/>
 <result pre="(28â€&quot;42) of HBV. Peptide 4B10 was shown to inhibit HBV" exact="infection" post="in both primary tupaia and human hepatocytes [225,71]. In"/>
 <result pre="novel membrane and extracellular proteins that are involved in HBV" exact="infection" post="such as lipoprotein lipase [50]. In addition to targeting"/>
 <result pre="patients [56,19,115]. Peptide-based vaccines have been developed to prevent HBV" exact="infection" post="in healthy individuals. It should be noted that in"/>
 <result pre="IgG antibodies against HBV. BM32 also protected rabbits from HIV" exact="infection" post="as effectively as the approved vaccine Engerix-B [43]. Immunoinformatic"/>
 <result pre="HEPLISAV-B (Dynavax Technologies Corporation). Peptides are also used for the" exact="diagnosis" post="of HBV. Traditionally, HBV DNA can be detected by"/>
 <result pre="diagnosis of HBV. Traditionally, HBV DNA can be detected by" exact="polymerase chain reaction" post="(PCR). HBsAg and HBcAg can be detected using immunostaining."/>
 <result pre="epitope 4: 134â€&quot;145 aa). rMEHB exhibited high sensitivity as a" exact="detection" post="agent in ELISA by presenting multiple epitopes for binding"/>
 <result pre="derived from HIV-2 helical region 2 of gp41that blocks HIV" exact="infection" post="at a sub-nanomolar concentration in both HIV-1 and HIV-2"/>
 <result pre="peptides derived from host cells that are involved in viral" exact="infection" post="have also been considered. An example is peptide 2C"/>
 <result pre="of effort, there is no available vaccine to prevent HIV" exact="infection" post="and progression. Most vaccines that have been developed have"/>
 <result pre="have failed to induce a protective immune response against HIV-1" exact="infection" post="in clinical trials. Eliciting neutralizing antibodies using gp120 as"/>
 <result pre="of diagnostic tests for AIDS; p24 antigen test for early-stage" exact="detection" post="and HIV-1 and HIV-2 antibody test for early to"/>
 <result pre="to chronic stage detection. Commonly used HIV tests range from" exact="immunofluorescence" post="to nucleic acid-based assays [99]. Peptides can be useful"/>
 <result pre="biosensors. Examples include an electrochemical peptide-based sensor developed for the" exact="detection" post="of HIV anti-p24 antibodies [70] and a bifunctional colorimetric/fluorescence"/>
 <result pre="immune response with unknown or poorly understood function. The viral" exact="infection" post="begins when the S protein binds to the host"/>
 <result pre="controlled in less than four months through the measures of" exact="infection" post="control instead of drug prevention or therapy [214]. During"/>
 <result pre="virus (HCV) therapy [233] and pediatric respiratory syncytial viral (RSV)" exact="infection" post="[42]. The reported uses of ribavirin in SARS cases"/>
 <result pre="from other treatments such as corticosteroids or other antivirals. Ribavirin" exact="treatment" post="for SARS was not tested in clinical trials, so"/>
 <result pre="we discuss the current developments in peptide-based therapies, vaccines, and" exact="detection" post="methods specific to SARS-CoV-1 and how they can help"/>
 <result pre="the literature. SARS-CoV-1 vaccines can be used to prevent viral" exact="infection" post="and transmission thereby aid in the control of outbreaks."/>
 <result pre="peptide-induced antiserum showed strong binding to recombinant SARS-CoV-1â€¯N protein by" exact="western blot." post="The immunogen N1 peptide reacted to sera of SARS"/>
 <result pre="the N protein to induce an immune response. Currently, SARS-CoV-1" exact="infection" post="is diagnosed by detection of viral RNA in clinical"/>
 <result pre="induce an immune response. Currently, SARS-CoV-1 infection is diagnosed by" exact="detection" post="of viral RNA in clinical samples by qRT-PCR, serological"/>
 <result pre="detection of viral RNA in clinical samples by qRT-PCR, serological" exact="detection" post="of specific antibody to SARS-CoV-1, and virus growth in"/>
 <result pre="development is needed to optimize the peptide sequence for accurate" exact="diagnosis" post="[133]. The surveillance of bat coronaviruses in the years"/>
 <result pre="EK1 peptide binds to the HR1 domain inhibiting the viral" exact="infection" post="as shown in S-mediated cell-cell fusion assays [221]. A"/>
 <result pre="Axon Neuroscience. Current laboratory tests for SARS-CoV-2 diagnostics involve the" exact="detection" post="of viral RNA by qRT-PCR and the detection of"/>
 <result pre="involve the detection of viral RNA by qRT-PCR and the" exact="detection" post="of anti-SARS-CoV-2 antibodies [186]. Tests based on qRT-PCR are"/>
 <result pre="N, S, polymerase, or open reading frame 1 (ORF1). Serological" exact="testing" post="is utilized for patients with mild symptoms or who"/>
 <result pre="therapeutics and vaccines in early-development and their application in the" exact="diagnosis" post="of viral infections. Peptide-based therapeutics hold great promises as"/>
 <result pre="Bioinformatics Tool For Allergenicity Prediction2020http://www.ddg-pharmfac.net/AllerTOP/index.html 5AlghrairZ.K.FernigD.G.EbrahimiB.Enhanced inhibition of influenza virus" exact="infection" post="by peptide-noble-metal nanoparticle conjugatesBeilstein J. Nanotechnol.1020191038104731165030 6AmanatF.KrammerF.SARS-CoV-2 vaccines: status"/>
 <result pre="against SARSBiochem. Biophys. Res. Commun.3081200314815112890493 40CimbroR.PetersonF.C.LiuQ.GuzzoC.ZhangP.MiaoH.Tyrosine-sulfated V2 peptides inhibit HIV-1" exact="infection" post="via coreceptor mimicryEBioMedicine102016455427389109 41ConlonJ.M.MechkarskaM.LukicM.L.FlattP.R.Potential therapeutic applications of multifunctional host-defense"/>
 <result pre="does not prevent relapse after discontinuation of analogues in the" exact="treatment" post="of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADNGut641201513914724555998"/>
 <result pre="novel drug targetsHepatol. Int.52201164465321484123 76GriponP.CannieI.UrbanS.Efficient inhibition of hepatitis B virus" exact="infection" post="by acylated peptides derived from the large viral surface"/>
 <result pre="Rev. Microbiol.38200559160016064053 93HsiehI.N.HartshornK.L.The role of antimicrobial peptides in influenza virus" exact="infection" post="and their potential as antiviral and immunomodulatory therapyPharmaceuticals (Basel)932016"/>
 <result pre="preliminary reportN. Engl. J. Med.2020 102JamjianM.C.McNichollI.R.Enfuvirtide: first fusion inhibitor for" exact="treatment" post="of HIV infectionAm. J. Health Syst. Pharm.611220041242124715259753 103JiangS.HeY.LiuS.SARS vaccine"/>
 <result pre="evolution of pathogenic coronavirusesNat. Rev. Microbiol.17201918119230531947 106JonesJ.C.TurpinE.A.BultmannH.BrandtC.R.Schultz-CherryS.Inhibition of influenza virus" exact="infection" post="by a novel antiviral peptide that targets viral attachment"/>
 <result pre="a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2Microb. Pathog.1452020104236 111KamaliA.HolodniyM.Influenza" exact="treatment" post="and prophylaxis with neuraminidase inhibitors: a reviewInfect. Drug Resist.6201318719824277988"/>
 <result pre="(HIV) assays, determine HIV-1/2 and OraQuick advance rapid HIV-1/2, for" exact="detection" post="of recent HIV seroconversionJ. Clin. Microbiol.461020083482348318685013 115KulinskiJ.M.TarakanovaV.L.VerbskyJ.Regulation of antiviral"/>
 <result pre="Sci. U. S. A.9351996218621918700906 117LeistnerC.M.Gruen-BernhardS.GlebeD.Role of glycosaminoglycans for binding and" exact="infection" post="of hepatitis B virusCell. Microbiol.101200812213318086046 118LiJ.ChenY.YuanN.ZengM.ZhaoY.YuR.a novel natural influenza"/>
 <result pre="in breast cancerPLoS One1042015e0124647 121LiawY.F.ChuC.M.Hepatitis B virus infectionLancet3739663200958259219217993 122LimE.K.GukK.KimH.ChungB.H.JungJ.Simple, rapid" exact="detection" post="of influenza a (H1N1) viruses using a highly sensitive"/>
 <result pre="related human coronavirus diseasesACS Cent. Sci.63202031533132226821 127LiuQ.SomiyaM.KurodaS.Elucidation of the early" exact="infection" post="machinery of hepatitis B virus by using bio-nanocapsuleWorld J."/>
 <result pre="with chronic hepatitis BJ. Hepatol.653201650951627210427 130Lopez-MartinezR.Ramirez-SalinasG.L.Correa-BasurtoJ.BarronB.L.Inhibition of influenza a virus" exact="infection" post="in vitro by peptides designed in silicoPLoS One8102013e76876 131LouZ.SunY.RaoZ.Current"/>
 <result pre="as hemagglutinin inhibitors for anti-influenza therapyJ. Med. Chem.531120104441444920476787 138MatsubaraT.UjieM.YamamotoT.AkahoriM.EinagaY.SatoT.Highly sensitive" exact="detection" post="of influenza virus by boron-doped diamond electrode terminated with"/>
 <result pre="Virol.93Pt 5201298098622258859 150Ning WangS.-Y.L.YangXing-LouHuangHui-MinZhangYu-JiGuoHuaLuoChu-MingMillerMaureenZhuGuangjianChmuraAleksei A.HaganEmilyZhouJi-HuaZhangYun-ZhiWangLin-FaDaszakPeterShiZheng-LiSerological evidence of Bat SARS-related coronavirus" exact="infection" post="in humans, ChinaVirol. Sin.3312018 151NyanguileO.Peptide antiviral strategies as an"/>
 <result pre="infectionsFront. Immunol.102019136631293570 152Oâ€™ConnellR.J.MerrittT.M.MaliaJ.A.VanCottT.C.DolanM.J.ZahwaH.Performance of the OraQuick rapid antibody test for" exact="diagnosis" post="of human immunodeficiency virus type 1 infection in patients"/>
 <result pre="antibody test for diagnosis of human immunodeficiency virus type 1" exact="infection" post="in patients with various levels of exposure to highly"/>
 <result pre="HIV-1Cell. Mol. Life Sci.681320112231224221553001 159PetersenJ.DandriM.MierW.LutgehetmannM.VolzT.von WeizsackerF.Prevention of hepatitis B virus" exact="infection" post="in vivo by entry inhibitors derived from the large"/>
 <result pre="deliveryMol. Pharm.15320181169117929436835 174Rerks-NgarmS.PitisuttithumP.NitayaphanS.KaewkungwalJ.ChiuJ.ParisR.Vaccination with ALVAC and AIDSVAX to prevent HIV-1" exact="infection" post="in ThailandN. Engl. J. Med.3612320092209222019843557 175ResourceI.A.MHC-II Binding Predictions2020 176RichardsonS.E.TellierR.MahonyJ.The"/>
 <result pre="in ThailandN. Engl. J. Med.3612320092209222019843557 175ResourceI.A.MHC-II Binding Predictions2020 176RichardsonS.E.TellierR.MahonyJ.The laboratory" exact="diagnosis" post="of severe acute respiratory syndrome: emerging laboratory tests for"/>
 <result pre="HIV vaccine, vacc-4x, restores geometric mean viral load set-point during" exact="treatment" post="interruptionPLoS One1412019e0210965 179RutW.Substrate specificity profiling of SARS-CoV-2 main protease"/>
 <result pre="neuraminidase: structure and functionActa Nat.1220092632 188SiskJ.M.FriemanM.B.Screening of FDA-approved drugs for" exact="treatment" post="of emerging pathogensACS Infect. Dis.19201540140227617922 189StadlerK.MasignaniV.EickmannM.BeckerS.AbrignaniS.KlenkH.D.SARS--beginning to understand a"/>
 <result pre="Pharm. Biopharm.103201615916627049970 200AIDS Data2020UNAIDS 201v2.0 T. http://www.cbs.dtu.dk/services/TMHMM/. 202VemulaS.V.ZhaoJ.LiuJ.WangX.BiswasS.HewlettI.Current approaches for" exact="diagnosis" post="of influenza virus infections in humansViruses8420169627077877 203VolzT.AllweissL.BenM.M.WarlichM.LohseA.W.PollokJ.M.The entry inhibitor"/>
 <result pre="glycoproteins: fusogens, antigens, and immunogensScience28053711998188418889632381 221XiaS.LiuM.WangC.XuW.LanQ.FengS.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
 <result pre="experiences and findingsJ. Hepatol.593201345045623669281 225YeX.ZhouM.HeY.WanY.BaiW.TaoS.Efficient inhibition of hepatitis B virus" exact="infection" post="by a preS1-binding peptideSci. Rep.620162939127384014 226YoshikawaM.Bioactive peptides derived from"/>
</results>
